InnoKeys acquires nimotuzumab assets from CIMYM BioSciences - MarketLine Financial Deals

InnoKeys acquires nimotuzumab assets from CIMYM BioSciences

InnoKeys acquires nimotuzumab assets from CIMYM BioSciences - MarketLine Financial Deals
InnoKeys acquires nimotuzumab assets from CIMYM BioSciences
Published Dec 03, 2012
2 pages — Published Dec 03, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

InnoKeys PTE, Ltd., a Singapore-based company, has acquired the assets relating to nimotuzumab from CIMYM BioSciences, Inc.

  
Source:
Document ID
MA131405_121212
Country
Country
Ticker
YM=CA
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "InnoKeys acquires nimotuzumab assets from CIMYM BioSciences" Dec 03, 2012. Alacra Store. Dec 07, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/InnoKeys-acquires-nimotuzumab-assets-from-CIMYM-BioSciences-2052-90205>
  
APA:
MarketLine Financial Deals. (2012). InnoKeys acquires nimotuzumab assets from CIMYM BioSciences Dec 03, 2012. New York, NY: Alacra Store. Retrieved Dec 07, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/InnoKeys-acquires-nimotuzumab-assets-from-CIMYM-BioSciences-2052-90205>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.